Guo, Fangjian

The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity

Guo, F., Moellering, D. R., & Garvey, W. T. (2014) · Obesity

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Function and Risk Factors

Cited by 202

Liver Retinol Transporter and Receptor for Serum Retinol-binding Protein (RBP4)

Alapatt, P., Guo, F., Komanetsky, S. M., Wang, S., Cai, J., Sargsyan, A., Rodríguez Díaz, E., Bacon, B. T., Aryal, P., & Graham, T. E. (2013) · Journal of Biological Chemistry

Retinoids in leukemia and cellular processesCholesterol and Lipid Metabolism

Cited by 150

Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age

Guo, F., Moellering, D. R., & Garvey, W. T. (2014) · Metabolic Syndrome and Related Disorders

Diabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 139

Development of a weighted cardiometabolic disease staging (CMDS) system for the prediction of future diabetes

Guo, F., & Garvey, W. T. (2015) · The Journal of Clinical Endocrinology & Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 44

Cardiometabolic disease staging predicts effectiveness of weight-loss therapy to prevent type 2 diabetes: pooled results from phase III clinical trials assessing phentermine/topiramate extended release

Guo, F., & Garvey, W. T. (2017) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 37